Julia Weisinger, MD: Obinutuzumab a Promising Option for Intolerant/Refractory iTTP скачать в хорошем качестве

Julia Weisinger, MD: Obinutuzumab a Promising Option for Intolerant/Refractory iTTP

Obinutuzumab was effective in treating patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) intolerant or refractory to rituximab with an acceptable safety profile, offering a potential option for this patient population. HCPLive spoke with Julia Weisinger, MD, a PhD candidate at Greater Paris University Hospitals, about the new data on obinutuzumab she presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. “There are not many clinical studies in TTP because it's a rare disease, and also, if there were some clinical studies, usually they were performed long ago, before the routine use of rituximab. So, we need new treatment options, and hopefully in the future, new guidelines what to use in TTP,” Weisinger said. https://www.hcplive.com/view/weisinge...